U.S. flag An official website of the United States government

U.S. Food and Drug Administration
  1. Home
  2. Tobacco Products
  3. Tobacco Science & Research
  4. Research
  5. Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs
  1. Research

Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs

Principal Investigator: Joseph Wu and Thomas Quertermous

Funding Mechanism: National Institutes of Health - Grant

ID number: 3R01HL141851-02S1

Award Date: 7/22/2020

Institution: Stanford University

Additional information about the pulmonary health effects of e-cigarettes would be useful, particularly given the growing number of e-cigarette or vaping use-associated lung injury (EVALI) cases. In this CTP Supplement to a parent grant (Modeling Tyrosine Kinase Inhibitor-Induced Vascular Dysfunction Using Human iPSCs), researchers will use a human induced pluripotent stem cell (iPSC)-based in vitro pulmonary toxicity screen to investigate the cellular, molecular, and genomic effects of six common e-cigarette components on lung tissue. Study aims are: (1) to generate iPSC-derived lung cells (i.e., alveolar epithelial cells, fibroblasts, smooth muscle cells, endothelial cells) from 12 existing healthy iPSC lines (6 male/6 female); and (2) to investigate the effects of e-cigarette components implicated in EVALI, including vitamin E acetate, tetrahydrocannabinol (THC), nicotine, propylene glycol, vegetable glycerin, and cannabidiol (CBD). Study findings may lead to new biomarkers and may inform future regulatory activities related to e-cigarettes.
 

Back to Top